Biotech Values

[oc631]

apparently we now learned that many nulls are in fact resistant to ribavirin - or else how do you explain the difference (even in these small numbers) between the treatment naive and null populations in the 7977 study

The poor results from GS-7977 monotherapy in GT2/GT3 patients proved ribavirin will be a essential part of oral therapy using the pyrimidine nuke. The data released last week appears to suggest what was lacking in interferon-based therapy for nulls is what's lacking now. Activity of the ribavirin component.